Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized study of mFOLFOXIRI versus mFOLFOX6 plus bevacizumab or cetuximab in first-line metastatic colorectal cancer
ChiCTR2000038258Phase 2Recruiting
- Sponsor
- Yunnan Cancer Hospital
- Start
- Sep 2020
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of fluorouracil, folinic acid, oxaliplatin, irinotecan, bevacizumab and 1 more in metastatic colorectal adenocarcinoma (mCRC) and colorectal adenocarcinoma (2 arms), sponsored by Yunnan Cancer Hospital. Primary endpoint: Objective response rate. Started Sep 2020; status: recruiting.
02
Drugs
fluorouracilfolinic acidoxaliplatinirinotecanbevacizumab
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)colorectal adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2000038258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000038258.